Making PROGRESS in stable patients post stroke or transient ischaemic attack: implications for general practice.
Stroke is a major cause of morbidity and mortality. Those who survive have a one in six chance of a further stroke in the ensuing five years. The perindopril protection against recurrent stroke study (PROGRESS) is the first specific trial to address whether blood pressure lowering in hypertensive or non-hypertensive patients with a history of stroke or transient ischaemic attack (TIA) would reduce subsequent cerebrovascular and cardiovascular events. Results show that treatment based on perindopril significantly reduces stroke (28%), cardiovascular events (26%) and heart failure (26%). Stable patients post stroke should be considered for perindopril, and indapamide if possible, along with other evidence based risk reduction treatments (e.g. aspirin, statins). Therapy can be initiated and monitored either from hospital outpatients or general practice or both in co-operation.
Jackson
G
G
Cardiothoracic Centre, St Thomas' Hospital, London, UK.
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D005194:Family Practice; D006801:Humans; D007190:Indapamide / Q000627:therapeutic use*; D002546:Ischemic Attack, Transient / Q000517:prevention & control*; D008875:Middle Aged; D020913:Perindopril / Q000627:therapeutic use*; D055502:Secondary Prevention; D020521:Stroke / Q000517:prevention & control*; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D007190:Indapamide; D020913:Perindopril